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Endoplasmic Reticulum Aminopeptidase 1
(ERAP1) Polymorphism Relevant to
Inflammatory Disease Shapes the Peptidome
of the Birdshot Chorioretinopathy-Associated
HLA-A*29:02 Antigen*□S
Carlos Alvarez-Navarro‡, Adrian Martín-Esteban‡, Eilon Barnea§, Arie Admon§,
and Jose´ A. Lo´pez de Castro‡¶
Birdshot chorioretinopathy is a rare ocular inflammation
whose genetic association with HLA-A*29:02 is the high-
est between a disease and a major histocompatibility
complex (MHC) molecule. It belongs to a group of MHC-
I-associated inflammatory disorders, also including anky-
losing spondylitis, psoriasis, and Behc¸et’s disease, for
which endoplasmic reticulum aminopeptidases (ERAP) 1
and/or 2 have been identified as genetic risk factors.
Since both enzymes are involved in the processing of
MHC-I ligands, it seems reasonable that common pep-
tide-mediated mechanisms may underlie the pathogene-
sis of these diseases. In this study, comparative immuno-
peptidomics was used to characterize >5000 A*29:02
ligands and quantify the effects of ERAP1 polymorphism
and expression on the A*29:02 peptidome in human cells.
The peptides predominant in an active ERAP1 context
showed a higher frequency of nonamers and bulkier amino
acid side chains at multiple positions, compared with the
peptides predominant in a less active ERAP1 background.
Thus, ERAP1 polymorphism has a large influence, shaping
the A*29:02 peptidome through length-dependent and
length-independent effects. These changes resulted in in-
creased affinity and hydrophobicity of A*29:02 ligands in an
active ERAP1 context. The results reveal the nature of the
functional interaction between A*29:02 and ERAP1 and sug-
gest that this enzyme may affect the susceptibility to bird-
shot chorioretinopathy by altering the A*29:02 peptidome.
The complexity of these alterations is such that not only
peptide presentation but also other potentially pathogenic
features could be affected. Molecular & Cellular Pro-
teomics 14: 10.1074/mcp.M115.048959, 1770–1780, 2015.
Several major histocompatibility complex class I (MHC-I)1
alleles are strongly associated with polygenic inflammatory
diseases, including birdshot chorioretinopathy (BSCR: A*29:
02), ankylosing spondylitis (AS: HLA-B*27), psoriasis (C*06:
02), and Behc¸et’s disease (HLA-B*51). In the three latter dis-
orders, ERAP1, an aminopeptidase of the endoplasmic
reticulum performing the final trimming of MHC-I ligands (1,
2), is also a risk factor and is in epistasis with the predisposing
MHC-I allele (3–5). These studies suggest common pathoge-
netic mechanisms involving the MHC-I bound peptidome.
ERAP2, a related enzyme that acts in concert with ERAP1 (6,
7), influences the susceptibility to BSCR (8), AS (although not
necessarily in epistasis with HLA-B*27) (9), Crohns disease
(10), and preeclampsia (11–13).
BSCR is a rare and severe form of bilateral posterior uveitis,
showing a progressive inflammation of the choroid and retina,
whose association with HLA-A*29 is the strongest for any
disease and MHC. The frequency of this allele is about 7% in
healthy individuals but 95% in BSCR patients (14, 15). This
association specifically concerns A*29:02 and not the closely
related allotype A*29:01 (8).
Genetic studies on BSCR also showed a highly significant
association within the LNPEP gene (rs7705093) in the 5q15
region, which includes the ERAP1 and ERAP2 genes. One
single nucleotide polymorphism (SNP) in this region
(rs10044354) correlated with ERAP2 expression. This was
confirmed at the protein level, leading to the conclusion that
ERAP2 expression predisposes to BSCR. Yet, an involvement
of functional ERAP1 polymorphisms, not determining protein
expression, was not excluded. These polymorphisms have a
large influence on the HLA-B*27 peptidome (16, 17). In con-
trast, the effects of ERAP2 on MHC-I peptidomes are poorly
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understood and are probably dependent on the particular
ERAP1 context since ERAP2 cooperates with ERAP1 in pep-
tide processing. Thus, the present study was conducted to
characterize A*29:02-bound peptidomes in various ERAP1
backgrounds and to determine the influence of ERAP1 poly-
morphism on the amounts and features of A*29:02 ligands in
human cells.
EXPERIMENTAL PROCEDURES
Cell Lines—PF97387 (HLA-A*29:02, B*44:03, C*16:01, DRB1*04),
MOU (HLA-A*29:02, B*44:03, C*16:01, DRB1*07:01, DRB4*01:01),
and SWEIG (HLA-A*29:02, B*40:02, C*02:02, DRB1*11:01, DRB3*02:
02) are human lymphoblastoid cell lines (LCL) homozygous for A*29:
02. They all were included in the reference panel of the 10th Interna-
tional Histocompatibility Workshop (18). The three cell lines were of
Caucasian origin and, to the best of our knowledge, from healthy
individuals. These LCL and the human lymphoid cell line C1R (19)
were cultured in RPMI 1640 medium with 10% fetal bovine serum
(Biowest, Nuaille´, France), 25 mM HEPES buffer, 20 mm L-glutamine,
penicillin and streptomycin.
ERAP Genotyping—The exons encompassing eight nonsynony-
mous SNPs in ERAP1 and 1 in ERAP2, as well as the noncoding
sequences including two SNPs associated with loss of ERAP2 ex-
pression (Table I) were sequenced as previously described (16).
Quantitative RT-PCR—This was done as in (16) except that stand-
ard curves using two ERAP1 variants differing at codon 730 and
cloned in pFastBac plasmids were used to estimate the amount of
each allele present in our samples.
Western Blotting—This was performed as described elsewhere
(20). ERAP1, ERAP2, and -tubulin were detected with the 6H9, 3F5
(both from, R&D Systems, Minneapolis, MN), or GTU88 (Sigma-Al-
drich, St. Louis, MO) mAbs, respectively.
Flow Cytometry—About 3  105 cells were washed twice with 200
l of PBS, centrifuged, and incubated with the 108–2C5 (IgG1; spe-
cific for folded HLA-A molecules) (21) or HCA2 mAb (IgG1; specific for
unfolded HLA-A heavy chain) (22) for 30 min at 4 °C at a final con-
centration of 30 and 10 g/ml of purified mAb, respectively. The cells
were washed three times with 200 l of PBS and incubated with an
FITC-conjugated anti-mouse IgG secondary antibody (eBioscience,
San Diego, CA), at 0.5 g/ml for 30 min and 4 °C. Finally, the cells
were washed three times with PBS and fixed with 1% of parafor-
maldehyde. The detection was carried out in a FACSCalibur instru-
ment (BD Biosciences, San Jose´, CA) using CellQuestTM Pro version
4.0.2. All data were analyzed using FlowJo version 7.5 software (Tree
Star, Inc., Ashland, OR).
Isolation of HLA-A*29:02-Bound Peptidomes—This was carried
out as previously described (23) with some modifications. Briefly,
about 2  109 cells were lysed in 1% Igepal CA-630 (Sigma) in the
presence of a mixture of protease inhibitors (Roche, Mannheim, Ger-
many). A*29:02/peptide complexes were specifically purified by affin-
ity chromatography using the HLA-A-specific 108–2C5 mAb (21) and
eluted with 0.1% TFA. A*29:02 ligands were isolated by filtering with
Vivaspin 2, cutoff 5,000 Da, (Sartorious Stedim Biotech, Gottingen,
Germany) according to the manufacturer’s instructions, concentrated
and subjected to reverse phase purification using OMIX tips (Varian
Inc. Palo Alto, CA) by elution with 50% acetonitrile in water and 0.1%
TFA. The eluted peptides were concentrated to about 100 l and
stored at 20 °C. For each cell line, three peptide preparations were
independently obtained from the same cell amounts.
Mass Spectrometry—The samples were analyzed in a Q-Exactive-
Plus mass spectrometer fitted with Ultimate 3000 RSLC nano-capil-
lary UHPLC (both from Thermo Fisher). The peptides were resolved
on a capillary column (75-m ID) pressure-packed as in (24) with
Reprosil C18-Aqua (Dr. Maisch, GmbH, Germany) resolved using
7–40% acetonitrile gradients in the presence of 0.1% formic acid for
180 min and 0.15 l/min. The dynamic exclusion was set to 20 s. The
top ten most intense masses were selected for higher-energy collision
dissociation fragmentations from the survey scan of m/z 300–1,800
AMU at resolution of 70,000. MS/MS spectra were acquired starting
atm/z 200 with a resolution of 17,500. The target value was set to 1
105 and the isolation window to 1.8 m/z. The maximum injection time
was set to 100 ms and normalized collision energy to 25 eV.
MS Data Analyses—The peptides were identified and quantified
using the MaxQuant software (version 1.4.0.8) (25) with the Androm-
eda search engine (26) using the human section of the UniProt/Swiss-
Prot database (release 2013 05, 20,255 entries) under the following
parameters: both ion precursor mass and fragment mass tolerance 20
ppm, false discovery rate (FDR) 0.01, and peptide-spectrummatching
(PSM) FDR 0.05, oxidation (M) as variable modification. The resulting
peptides were filtered to eliminate the identifications derived from the
reverse database, as well as from common contaminants. To avoid
any differences in the peptide intensity attributable to HLA-A29 ex-
pression, the intensity assigned to each peptide sequence in a given
cell line was normalized by dividing that intensity with the added
intensities of all sequenced peptides in each independent experiment.
MHC Binding Affinity—This was estimated as previously described
(27) using the NetMHCcons 1.0 Server at http://www.cbs.dtu.dk/
services/NetMHCcons/. This server uses three different methods to
more accurately estimate the theoretical MHC binding affinity of
peptides with 8–15 residues. Statistical analyses were performed
with the Mann–Whitney test.
Hydropathy Analysis—This was estimated as the GRAVY score,
using the hydropathy index of Kyte and Doolittle (28). A higher GRAVY
score indicates higher hydrophobicity. Statistical analyses were per-
formed with the Mann–Whitney test.
RESULTS
The HLA-A*29:02 Peptidome—This was characterized by
mass spectrometry (MS) of the natural ligands isolated from
three A*29:02 homozygous LCL with distinct ERAP1 back-
grounds and no expression of ERAP2 (Table I). A total of 5,584
peptides were identified (Table S1), well beyond the 300
previously reported human A*29:02 ligands (29, 30). Their
length and molecular weight (MW) distributions were similar to
TABLE I
ERAP1 and ERAP2 variants expressed in A*29:02- positive cell lines
ERAP1
SNP Polymorphism
PF97387 MOU SWEIG
Base AAa Base AAa Base AAa
rs26653 P127R G R C P C P
rs26618 I276M A I A/G I/M A I
rs27895 G346D G G G G G G
rs2287987 M349V A M A M A M
rs30187 K528R A K G R A/G K/R
rs10050860 D575N G D G D G D
rs17482078 R725Q G R G R G R
rs27044 Q730E C/G Q/E G E C/G Q/E
ERAP2
rs2549782 K392N G/T K/N T N G/T K/N
rs2248374 noncoding A/G – G – A/G –
rs10044354 noncoding C – C – C –
a AA: amino acid residue.
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other human MHC-I molecules (Figs. 1A and 1B). The main
anchor motif was C-terminal Y (87.7%). A secondary motif
consisted of aliphatic/aromatic P2 residues (70%) and L at
position PC-2 (30.2%) (Figs. 1C and 1D). With the exceptions
mentioned, the frequency of any single residue at any peptide
position was 20%, indicating a high allowance throughout
(Fig. 1C). This pattern was globally maintained in all peptide
lengths, although small length-dependent changes in residue
frequencies (i.e.: F2, I3) were occasionally observed (Fig. S1).
ERAP1 and ERAP2 Polymorphism and Expression in A*29:
02-Positive Cell Lines—None of the three cell lines used in this
study expressed ERAP2 (Fig. 2A). The ERAP1 protein was
present in PF97387, MOU and SWEIG in the ratios 1:0.5:0.06
(Fig. 2B). The higher expression level of ERAP1 variants with
K528 (PF97387) relative to those with R528 (MOU) has been
previously reported (31, 32) and is generally observed. The
amount of free HLA-A heavy chain at the cell surface of
SWEIG was about 23% of the total HLA-A*29. This was
approximately double the amount in the two other LCL (Fig.
2C). Increased cell surface dissociation of A*29:02 in SWEIG
is consistent with the known effect of the absence of ERAAP,
the mouse ortholog of ERAP1, on decreasing the affinity of
MHC-I/peptide complexes (33).
Sequencing was used to genotype eight nonsynonymous
ERAP1 polymorphisms, including those relevant in other
MHC-I-associated diseases (Table I). The K528R mutation
presumably accounts for the lower expression of ERAP1 in
MOU, relative to PF97387, as K528 correlates with higher
ERAP1 expression. The Q730 transcript in PF97387 was
2.8-fold more abundant than E730, as determined by quan-
titative RT-PCR. This demonstrates the codominant expres-
sion of both alleles and is compatible with a higher expres-
sion of the Q730 variant at the protein level. The noncoding
polymorphisms rs2248374 (34) and rs10044354 (8) are both
associated with lack of ERAP2 expression. As all three cell
lines were homozygous for the loss-of-expression allele of
rs10044354 (C) (Table I), this explains the absence of
ERAP2.
High sharing of A*29:02 Ligands Among Cell Lines—The
distinct contexts of the three cell lines allowed us to address
the effect of ERAP1 polymorphism and expression on the
A*29:02 peptidome through quantitative pairwise compari-
FIG. 1. General features of the A*29:
02 peptidome. A total of 5,584 A*29:02
ligands from three A*29:02 homozygous
cell lines were identified and analyzed as
follows. (A) Length distribution. (B) MW
distribution. The percentage of peptides
is indicated on top of each bar. (C) Res-
idue frequencies (RF) at the three N-
terminal (P1-P3) and three C-terminal
(PC-2-PC) positions of the identified
peptides. The dotted line indicates a RF
of 20%. (D) Individual residues were
grouped according to their chemical fea-
tures: basic (R, K, H), acidic (D, E), ali-
phatic (A, C, L, I, V, M), polar (N, Q, S, T),
aromatic (F, Y, W), and others (G, P). The
joint RF of each group is indicated.
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sons. With PF97387/MOU, the combined effect of residues
R127P, K528R, and QE730E was examined. With the com-
parisons involving SWEIG, we assessed the influence of low
ERAP1 expression, relative to variants with distinct activity.
Heterozygosis at residue 276 in MOU must be noted, al-
though there is no evidence that this polymorphism affects
ERAP1 function (35).
The A*29:02 peptidome of each cell line was characterized
from three independent preparations using the same number
of cells in identical conditions. The amount of any given pep-
tide was estimated as the intensity of the ion peaks assigned
to that peptide, relative to the total intensity of the identified
peptides in that experiment, designated as normalized inten-
sity. The amounts of individual peptides in each cell line were
the mean values from all three experiments. The number of
peptides identified from each cell line and the shared peptides
among cell line pairs are shown in Table II. Pearson correla-
tion of the normalized intensity of shared peptides among cell
line pairs indicated a high degree of linearity in the relative
peptide amounts (r: 0.8710–0.9266) in all cases (Fig. S2). The
fact that these values were somewhat lower in the compari-
sons involving SWEIG is compatible with the possibility that
the presence of ERAP1 (PF97387/MOU) increases the linear-
ity of peptide levels.
Influence of ERAP1 Polymorphism and Expression on the
Length of A*29:02 Ligands—The length and MW distribution
of the identified A*29:02 ligands was very similar in all three
cell lines (Fig. S3), suggesting that the global peptidome com-
parisons lacked resolution to detect an influence of ERAP1 on
particular peptide subsets. Thus, we performed three pairwise
comparisons, PF97387/MOU, PF97387/SWEIG, and MOU/
SWEIG, based on the relative intensity of the ion peaks cor-
responding to any given peptide in each of the two cell lines.
Shared peptides were classified in three subsets, according
to the normalized intensity ratio (IR) of the corresponding ion
peaks: IR1–1.5, IR1.5–3, and IR3. This subdivision was
arbitrarily set based on the assumption that quantitative ef-
fects of ERAP1 on the expression levels of MHC-I ligands
should be best observed among peptides showing the max-
imal intensity differences among cell lines. It was used in
previous studies from our laboratory to reveal the effects of
ERAP1 polymorphism on the HLA-B*27 peptidome (16, 17).
The relationship of the IR subsets to the statistical signifi-
cance of the intensity differences observed in the pairwise
peptidome comparisons among cell lines is shown in Fig. 3.
The length of the peptides from each subset of one cell line
was compared with that of the same subset in the other cell
line (Fig. 4). The IR3 subset from PF97387 showed a higher
percentage of 9-mers and lower percentage of longer pep-
tides than the corresponding subset from MOU (Fig. 4A). In
the comparisons involving SWEIG (Figs. 4B and 4C), the IR3
peptides from this cell line tended to be longer than the
corresponding peptides in the other cell lines in the following
FIG. 2. ERAP1 and ERAP2 expres-
sion among cell lines. ERAP2 (A) and
ERAP1 (B) expression was assessed by
Western blotting. Gamma-tubulin- was
used as internal control. Representative
experiments are shown. ERAP1 was nor-
malized as the ERAP1/-tubulin ratio to
compare the expression levels among cell
lines (lower panel). These data are means
of three experiments. (C) Surface expres-
sion of folded and unfolded A*29:02 was
assessed using the 108–2C5 and HCA2
mAbs, respectively, to establish the fold-
ed/unfolded HLA-A ratio in each cell line.
The data are the mean  S.D. of at least
three experiments.
TABLE II
Shared A*29:02 ligands among cell lines in pairwise comparisons
Comparison Ligands Shareda % Shareda PCb
PF97387/MOU 4,931/5,075 4,583 92.9/90.3 0.9266
PF97387/SWEIG 4,931/3,999 3,701 75.1/92.5 0.8710
MOU/SWEIG 5,075/3,999 3,747 73.8/93.7 0.8759
a Number and percentage of shared A*29:02 ligands between the
cell lines compared. The % sharing corresponding to the cell line with
less identified ligands (in boldface) was considered as the most
reliable value.
b PC: Pearson correlation of the normalized intensities of the
shared peptides (Fig. S2): all values were statistically significant: p 
.0001.
ERAP1 and the A*29:02 Peptidome
Molecular & Cellular Proteomics 14.7 1773
FIG. 3. Volcano plots showing the statistical significance of the of the IR values of the shared A*29:02 ligands in the indicated
comparisons among cell lines. The horizontal line indicates the threshold of statistical significance (p: 0.05), which was assessed by the t test.
The vertical lines indicate the IR values of 1.5 (discontinuous) and 3.0 (continuous), respectively. Only the shared peptides for which more than
one intensity value was obtained in the two cell lines compared are included: 3,822, 2,816, and 2,865 peptides in PF97387/MOU, in
PF97387/SWEIG, and MOU/SWEIG, respectively.
FIG. 4. Length distribution of A*29:02 ligands as a function of their relative abundance in distinct ERAP1 contexts. (A) A total of 4,583
shared peptides were identified in the PF97387/MOU comparison. They were classified in the indicated subsets on the basis of the intensity
ratio (IR) of the corresponding ion peaks. The peptides of a given length in each subset from one cell line were compared with those of the
corresponding subset from the other cell line. From top to bottom, peptides showing IR1.0 to 1.5, IR1.5 to 3.0 and IR3.0, respectively,
were compared. (B) A total of 3,701 shared peptides identified in PF97387/SWEIG were compared as in panel A. (C) The 3,747 shared
peptides identified in MOU/SWEIG were analyzed as in panels A and B. In each panel, the differential mean length between the two peptide
subsets compared (	Length) is indicated. Statistically significant differences (p  .05) were determined by the 2 test and labeled with
asterisks (*).
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order: SWEIG(ERAP1low)MOU(P127/R528)PF97387(R127/
K528). Since 9-mers are the peptides with optimal length for
MHC-I binding, these results indicate that ERAP1 optimizes
the length of A*29:02 ligands as a function of its enzymatic
activity and expression level, both of which are known to be
higher with K528.
Length-Independent Effects of ERAP1 on A*29:02 Li-
gands—To investigate possible length-independent differ-
ences in the MW of A*29:02 ligands among cell lines, further
analyses were carried out with peptides of the same length.
First, the 9-mers found only in one cell line were considered
(Fig. S4). The mean MW of these peptides was: PF97387
(1,125.4 Da)  SWEIG (1,096.0 Da)  MOU (1,073.9 Da).
Second, the MW distribution of the shared 9-mers and 10-
mers in the various IR subsets (1–1.5, 1.5–3, and3) from
the pairwise comparisons among cell lines was examined. In
PF97387/MOU a shift of the predominant 9-mers from
PF97387 (IR1.5 and IR3 subsets) toward higher MW, rel-
ative to MOU, was observed (Fig. 5A). In the comparisons
involving SWEIG, the predominant 9-mers from this cell line
(IR1.5 and IR3 subsets) showed MW distributions shifted
toward lower values relative to PF97387 (Fig. 5B) and little
difference relative to MOU (Fig. 5C). Similar results were ob-
tained with 10-mers (Fig. S5).
These results indicate that, in addition to altering the length
of A*29:02 ligands, ERAP1 polymorphism and expression in-
fluence their MW in a length-independent way so that pep-
tides with bulkier residues are predominant in the context of
the most active variant.
Position-Dependent Differences among A*29:02 Ligands
from Distinct Cell Lines—The basis of the length-independent
differences in MW among A*29:02 ligands was analyzed by
comparing the mean side-chain volume of the most predom-
inant 9-mers (IR3) in the different pairwise comparisons at
each peptide position (Fig. 6). The IR3 9-mers from PF97387
had bulkier P1-P6 and P8 residues than the corresponding
FIG. 5. Length-independent differences among A*29:02 ligands expressed on distinct ERAP1 contexts. (A) A total of 3,157 shared
nonamers in PF97387/MOU were classified and compared on the basis of their MW distribution as in Fig. 3. (B) The 2,559 shared nonamers
in PF97387/SWEIG were comparatively analyzed as in panel A. (C) The 2,577 shared nonamers in MOU/SWEIG were compared as panels A
and B. In each panel, the differential mean MW between the peptide subsets compared (	MW) is indicated.
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peptides from MOU (Fig. 6A). The largest differences were at
P1 and P2. They correlated with the volume of individual
residues and not with their susceptibility to ERAP1 trimming
(Figs. 6B and 6C).
A similar analysis carried out with the IR3 9-mers from
PF97387 or MOU, relative to those from SWEIG (Fig. S6),
showed that the mean side-chain volume of residues P1-P8
was higher in PF97387, whereas the differences were essen-
tially leveled out in most positions, except P1, P2, and P7, in
MOU/SWEIG. For P1 and P2, the relative residue frequencies
again correlated better with side-chain volume than with sus-
ceptibility to ERAP1.
Highly Active ERAP1 Optimizes the Affinity of A*29:02 Li-
gands through Length-Dependent and Length-Independent
Effects—We examined whether the effect of ERAP1 on both
peptide length and side chain volume altered the theoretical
binding affinity of A*29:02 ligands. The 9-mers showed higher
affinity than longer peptides in all 3 cell lines (Fig. 7A). Since a
highly active ERAP1 variant increased the frequency of the
most abundant 9-mers, relative to longer peptides, in pairwise
comparisons (Fig. 4), this implies a length-dependent optimi-
zation of affinity in the A*29:02 peptidome. In a similar analysis
performed on published peptide data bases, higher theoreti-
cal affinity of 9-mers relative to longer peptides was also
observed among HLA-A*02 ligands (36) but not in HLA-B*07
(36) or B*27:05 (37).
We next compared the affinity of A*29:02 ligands showing
differential expression in PF97387/MOU, PF97387/SWEIG,
and MOU/SWEIG. The peptides with IR1 from PF97387
showed higher affinity than those from MOU or SWEIG (Fig.
7B). This was also true when only 9-mers were considered to
assess length-independent effects (Fig. 7C). In MOU/SWEIG,
the predominant peptides from MOU showed an affinity dis-
tribution displaced toward lower affinity values, relative to
those from SWEIG, particularly among 9-mers. However, the
average affinity of the corresponding peptides from MOU was
higher than in SWEIG (mean IC50: 520 versus1,135 nM and
372 versus 910 nM, for all peptide sizes and 9-mers, respec-
tively). This was due to the higher percentage of very low
affinity A*29:02 ligands among the predominant peptides from
the ERAP1low cell line (Fig. 7B and 7C).
We reasoned that the effect of ERAP1 on the affinity of
A*29:02 ligands might be best revealed with the peptides
showing the largest expression differences among cell lines.
Thus, the same analyses were carried out on the IR1–1.5,
IR1.5–3, and IR3 subsets (Fig. S7). As expected, in
PF97387/MOU, the peptides from PF97387 showed higher
affinity in all three IR subsets but especially in IR3 and
IR1.5–3, both for all lengths and for 9-mers. A similar trend
was observed in PF97387/SWEIG. In MOU/SWEIG, an affinity
distribution of the peptides from MOU shifted toward lower
affinity values was observed, particularly among 9-mers, in
the IR3 and IR1.5–3 subsets but with a higher percentage
of very low affinity ligands in SWEIG.
The predominant 9-mers from PF97387 were more hydro-
phobic than those from MOU or SWEIG in the respective
comparisons, whereas marginal or no differences were ob-
served between MOU and SWEIG (Fig. S8). This result paral-
lels the length-independent affinity differences (Fig. S7B) and
suggests that the basis for the length-independent influence
FIG. 6. Position-dependent effects
of ERAP1 on A*29:02 ligands. The
IR3 nonamers from each cell line in
PF97387/MOU (black and gray, respec-
tively) were compared. (A) Mean side-
chain volumes at the indicated peptide
positions were calculated and compared
using the residue frequency (RF) and the
experimental side-chain volume of each
amino acid. (B) RF values at P1 were
ordered as a function of the side-chain
volume (upper panel) or ERAP1 suscep-
tibility (52) (lower panel). (C) The RF val-
ues at P2 were ordered and compared
as above.
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of ERAP1 polymorphism on the affinity of A*29:02 ligands is
the increased hydrophobicity of the peptides resulting from
selection of bulkier residues by the more active variant.
DISCUSSION
The joint association of A*29:02 and ERAP2 with BSCR
strongly suggests a peptide-dependent pathogenetic mech-
anism. Thus, the characterization of the A*29:02-bound pep-
tidome and its shaping by the aminopeptidases involved in
the processing of MHC-I ligands seems critical to our under-
standing of BSCR pathogenesis.
ERAP2 might influence BSCR in various ways. It may gen-
erate a specific autoantigen. Alternatively, ERAP2 may be
required for specific epitope production only in certain ERAP1
contexts, being dispensable otherwise. ERAP2 facilitates an-
tigen processing by ERAP1 through its complementary trim-
ming specificity (6). Thus, ERAP2 might be particularly rele-
vant in the context of low activity ERAP1 variants. A third
possibility is that, since ERAP2 efficiently degrades 8-mers
and shorter peptides, it might influence in this way the sub-
strate-inhibition kinetics of ERAP1 trimming (20, 38) or the
affinity-dependent peptide exchange on the MHC-I molecule
mediated by very small peptides (39, 40).
We analyzed the effect of functional ERAP1variants, and of
decreased enzyme expression, on the A*29:02 peptidome.
The focus was on the amounts of shared ligands presented in
distinct contexts since it is formally difficult to establish ab-
sence of individual epitopes when they are not detected by
MS. Substantial alterations affecting many peptides occurred
at two different levels: modulation of peptide length and mod-
ulation of sequence features based on differential selection of
amino acid side chain volumes.
The effect of ERAP1 polymorphism on the length of A*29:02
ligands was analogous as in B*27:04 (16), consisting of a
FIG. 7. Length-dependent and length-independent influence of ERAP1 on the affinity of A*29:02 ligands. (A) Predicted binding affinity
of the nonamers and longer peptides (10-mers) from the indicated cell lines. The bars indicate the median of the corresponding values. The
average IC50 values for 9-mers/10-mers were 888/1619 nM, 1014/1677 nM and 675/1199 nM for PF97387, MOU and SWEIG, respectively
(B) Predicted binding affinities of the predominant (IR1) A*29:02 ligands in the pairwise comparisons between the indicated cell lines. Average
IC50 values were 946/1265 nM (PF97387/MOU), 485/1026 nM (PF97387/SWEIG) and 520/1135 nM (MOU/SWEIG) (C) Length-independent
effects of ERAP1 on the affinity of A*29:02 ligands were assessed by comparing the IR1 nonamers. p values, as determined with the
Mann–Whitney test, are indicated. Average IC50 values were 659/1053 nM (PF97387/MOU), 325/849 nM (PF97387/SWEIG), and 372/910 nM
(MOU/SWEIG). In panels B and C note that in the MOU/SWEIG comparison, the affinity distribution, as indicated by the median, is shifted
toward lower values (higher IC50) in MOU. However, the average IC50 values indicate a higher average affinity of the peptides from MOU due
to a higher percentage of A*29:02 ligands with very low affinity in SWEIG.
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higher percentage of 9-mers, relative to longer peptides,
among those predominant in the more active context. Ab-
sence of ERAP1 also results in longer MHC-I ligands (41, 42).
This was also true for A*29:02, particularly when compared
with a highly active ERAP1 background.
The length-independent influence on amino acid side chain
volumes demonstrates a further level of ERAP1-induced al-
terations in the A*29:02 peptidome distinct from substrate
length and susceptibility of the P1 residue to trimming. It also
confirms that the peptide sequence downstream the N termi-
nus modulates ERAP1 processing (43). The basis for this
effect is to be found in the role of substrate affinity on pro-
moting the conformational transition in ERAP1 required for
efficient peptide trimming (44, 45). The specific reasons for
the predominance of A*29:02 ligands with bulkier side chains
in the more active ERAP1 context are less obvious. One
possibility is a size effect of residue 730, located in the sub-
strate binding site of ERAP1. Q730 is 5.4 Å3 bigger than E730.
Presumably, substrates with smaller side chains are better
accommodated in the ERAP1 variant of PF97387 with Q730.
This variant also has K528, which confers higher activity than
R528, present in MOU (3, 17, 20, 35, 38, 44). Both effects may
lead to increased destruction of substrates with smaller side
chains by the ERAP1 variant in PF97387, resulting in higher
availability of peptides with bulkier side chains for binding to
A*29:02. The larger binding site of the ERAP1 variant in MOU,
with only E730, and its lower activity, due to R528, would
explain the low selection of A*29:02 ligands relative to SWEIG,
on the basis of side chain volumes.
Increased expression of free MHC-I heavy chain at the cell
surface in the ERAP1low background of SWEIG was also ob-
served in HLA-B*27 (46). The higher expression of free HLA-A
heavy chain in SWEIG relative to MOU can be explained by the
lower average affinity of the peptides from SWEIG and the
higher percentage of very low affinity ligands among those
predominant in this cell line. In addition, it is conceivable that, in
the absence of ERAP1, a specific subpopulation of peptides
binds A*29:02 with low affinity and dissociates at the cell sur-
face. These peptides would hardly be detected in our analyses
since this was performed after immunopurification of properly
folded peptide/MHC complexes.
There are no studies quantifying the effects of ERAP2 in the
context of distinct ERAP1 variants. We propose that ERAP1
influences the susceptibility to BSCR and that the role of
ERAP2 in this disease may be particularly prominent in the
context of ERAP1 alleles of low activity. Without ruling out a
pathogenetic ERAP2-dependent epitope, the influence of
ERAP1 on the A*29:02 peptidome may be more complex. For
instance, killer cell immunoglobulin-like receptors are risk fac-
tors for BSCR in A*29:02
 individuals (47, 48). ERAP1 was
recently suggested to modify, killer cell immunoglobulin-like
receptor engagement to the MHC-I molecule by altering the
affinity of MHC-I-bound peptides (49). Thus, the influence of
ERAP1 polymorphism on the affinity of A*29:02 ligands may
alter natural killer (NK)-related functions in these individuals,
depending on their, killer cell immunoglobulin-like receptor
phenotypes, influencing in this way their susceptibility to
BSCR. Substantial peptidome alterations may also influence
general and potentially pathogenic features of the molecule,
such as folding and stability (50).
Future research on BSCR pathogenesis might benefit from
a wider standpoint where a comprehensive view of the mo-
lecular biology of HLA-A*29 is taken into account. This con-
cept, which is being increasingly substantiated by research in
HLA-B*27 (51), might reflect common pathogenetic mecha-
nisms underlying the joint association of MHC-I and ERAP1/2
in inflammatory diseases.
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